Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy

Next Previous
X
Search
Trial Profile

Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NPI-002 (Primary)
  • Indications Cataracts
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Nacuity Pharmaceuticals

    • Most Recent Events

    • 30 Apr 2024 According to a Nacuity Pharmaceuticals media release, company announced that the first patients have been implanted in the final cohort.An independent Data Safety Monitoring Board (DSMB) recommended proceeding with the final cohort after a positive safety review. The final cohort of the trial is actively enrolling patients for clinical sites at The Royal Adelaide Hospital (RAH) in Adelaide, South Australia, and personalEYES in Parramatta, New South Wales, Australia.
    • 07 Feb 2024 Planned End Date changed from 1 Apr 2024 to 1 Feb 2025.
    • 07 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Oct 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top